Autolus Therapeutics (NASDAQ:AUTL) Shares Gap Up - Here's Why

Autolus Therapeutics plc (NASDAQ:AUTL - Get Free Report)'s stock price gapped up before the market opened on Tuesday . The stock had previously closed at $1.91, but opened at $1.98. Autolus Therapeutics shares last traded at $2.09, with a volume of 2,573,793 shares.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on AUTL. Needham & Company LLC reaffirmed a "buy" rating and issued a $10.00 target price on shares of Autolus Therapeutics in a report on Thursday, April 10th. Wells Fargo & Company dropped their price objective on Autolus Therapeutics from $8.00 to $6.00 and set an "overweight" rating on the stock in a report on Friday, March 21st. Finally, Truist Financial cut their price objective on Autolus Therapeutics from $11.00 to $10.00 and set a "buy" rating for the company in a research report on Tuesday, April 1st. Five investment analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has an average rating of "Buy" and an average target price of $9.32.

Autolus Therapeutics Trading Up 2.6%

The firm has a 50 day moving average of $1.43 and a two-hundred day moving average of $1.99. The stock has a market capitalization of $570.87 million, a PE ratio of -1.77 and a beta of 1.77.

Autolus Therapeutics (NASDAQ:AUTL - Get Free Report) last issued its quarterly earnings data on Thursday, May 8th. The company reported ($0.26) earnings per share for the quarter, missing analysts' consensus estimates of ($0.24) by ($0.02). The firm had revenue of $8.98 million for the quarter, compared to analyst estimates of $1.59 million. Equities research analysts forecast that Autolus Therapeutics plc will post -0.94 EPS for the current year.

Institutional Investors Weigh In On Autolus Therapeutics

Several institutional investors and hedge funds have recently modified their holdings of AUTL. Jane Street Group LLC bought a new stake in shares of Autolus Therapeutics in the 4th quarter valued at about $26,000. Barclays PLC lifted its position in shares of Autolus Therapeutics by 1,094.3% in the fourth quarter. Barclays PLC now owns 11,859 shares of the company's stock worth $28,000 after purchasing an additional 10,866 shares in the last quarter. Daiwa Securities Group Inc. lifted its position in Autolus Therapeutics by 55.5% during the 4th quarter. Daiwa Securities Group Inc. now owns 23,743 shares of the company's stock worth $56,000 after buying an additional 8,479 shares in the last quarter. Virtus ETF Advisers LLC raised its holdings in Autolus Therapeutics by 29.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 26,429 shares of the company's stock worth $62,000 after acquiring an additional 6,081 shares in the last quarter. Finally, Invesco Ltd. increased its position in shares of Autolus Therapeutics by 53.3% during the 1st quarter. Invesco Ltd. now owns 32,738 shares of the company's stock worth $51,000 after purchasing an additional 11,381 shares during the last quarter. Institutional investors and hedge funds own 72.83% of the company's stock.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer and autoimmune diseases. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which is in a Phase 1 clinical trial in pediatric patients with relapsed or refractory ALL; AUTO4, a programmed T cell investigational therapy for the treatment of peripheral T-cell lymphoma targeting TRBC1 and TRBC2; AUTO6NG, a programmed T cell investigational therapy targeting GD2 in development for the treatment of neuroblastoma; and AUTO8, a product candidate to treat multiple myeloma.